Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07423650

Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy

Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy: A Randomized Controlled Double-Blind Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
93 (estimated)
Sponsor
Iuliu Hatieganu University of Medicine and Pharmacy · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to determine whether continuous nefopam administration, as part of a multimodal analgesia strategy, reduces opioid consumption and improves patient satisfaction after pancreatoduodenectomy. The main questions are: Does nefopam administration reduce opioid consumption after pancreatoduodenectomy? Does nefopam administration reduce postoperative pain levels after pancreatoduodenectomy? Researchers will compare two other analgesic strategies, namely continuous lidocaine infusion and epidural analgesia, to assess whether they lead to better outcomes. Participants will complete the QoR-15 questionnaire and report their pain levels at predefined time points before and after surgery.

Conditions

Interventions

TypeNameDescription
DRUGNefopam 120mg/day infusionNefopam administration will start in the intraoperative period and continue for 48 hours in the postoperative period
DRUGLidocaine InfusionLidocaine infusion will begin in the intraoperative period and continue in the postoperative period for 48 hours
DRUGPeriduralThis group will receive the stardad practice in our hospital, peridural analgesia alongside a multimodal analgesic approach involving paracetamol 4g/day
DRUGMultimodal IV analgesiaStandard postoperative multimodal pain management regimen

Timeline

Start date
2026-03-01
Primary completion
2026-10-01
Completion
2026-10-01
First posted
2026-02-20
Last updated
2026-03-24

Locations

1 site across 1 country: Romania

Source: ClinicalTrials.gov record NCT07423650. Inclusion in this directory is not an endorsement.